Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting

Loading news article.

Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting | WAPE

Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting

Article summary

Related companies

Comments —